Pharma frets over CDER chief Woodcock's retirement; Vivus study finds Qsymia helped stave off diabetes;

@FiercePharma: Top 10 Drugmakers in Emerging Markets--our latest special report. Feature | Follow @FiercePharma

@CarlyHFierce: Teva: Copying GlaxoSmithKline's Advair too tough for success before 2018. ICYMI yesterday | Follow @CarlyHFierce

> As FDA bigwig Dr. Janet Woodcock prepares to retire next year, drugmakers are worrying about who will replace her. Report

> Vivus ($VVUS) said high-risk patients who used its weight loss drug Qsymia were more than 70% less likely to develop diabetes, compared with patients on placebo. Report

> A federal judge rejected two drugmakers' move to keep secret their reports submitted to the federal government to comply with corporate integrity agreements. Report

> The generic drugmaker Lannett closed its public stock offering, which delivered net proceeds of $71.5 million. Report

> The state of Missouri said it would return an anesthetic it planned to use in executions after its manufacturer, Germany's Fresenius Kabi, protested. Report

> Fitch Ratings figures biosimilars uptake will be stronger in the U.S. than it has been in Europe, though acceptance may be slow at first. Report

Medical Device News

@FierceMedDev: Medtronic jumps into hemodialysis business through India partnership. ICYMI yesterday | Follow @FierceMedDev

@MarkHFierce: The head of Roche molecular diagnostics spoke to FierceDiagnostics recently about two key future products. More | Follow @MarkHFierce

@MichaelGFierce: Check out this week's FierceDrugDelivery newsletter! RNAi roundup & stem cell drug delivery action. Report | Follow @MichaelGFierce

> Are medical device companies invited to the biotech IPO party? Editor's corner

> Boston Scientific kicks off drug-eluting stent trial as sales wane. Story

> Quest warns reimbursement pressures, test volume declines will dampen Q3. More

> FDA panel casts doubt on CardioMEMS' heart failure diagnostic. Article

Biotech News

@FierceBiotech: Popular yesterday: 10 top drugs in biopharma's late-stage pipeline. Feature | Follow @FierceBiotech

@JohnCFierce: Few months after $60M C series and Forest deal, Trevena files for $86M IPO. SEC filing | Press release | Follow @JohnCFierce

@DamianFierce: MacroGenics has up-sized its IPO, now seeking $80M amid biotech blitz. ICYMI yesterday | Follow @DamianFierce

@EmilyMFierce: 3-D printing builds bacterial metropolises. More via ScienceNews | Follow @EmilyMFierce

> Google visionaries ready to invest a fortune in revolutionizing aging process. Article

> Takeda punts $620M antibody licensing pact with Immunomedics. Story

> Gilead scores early PhIII success for idelalisib in chronic lymphocytic leukemia. More

Pharma Manufacturing News

@EricPFierce: Will McKesson and AmerisourceBergen now face off in Europe? Article | Follow @EricPFierce

> Catalent moves on Brazil VMS, softgel market. News

> Vetter putting $100M into its production network. Report

> Teva looks for big savings from procurement, manufacturing. Story

> Feds fight drug imports Maine now allows. More

> BioCentury finds FDA has $270M in GDUFA, PDUFA fees in hand. Item

Vaccines News

> WHO prequalification moves China into global vaccine arena. Item

> Novartis opening vaccine R&D lab in North Carolina. Report

> Takeda's norovirus vaccine misses endpoint in early-phase trial. Story

> GSK targets 2015 launch for malaria vaccine. Article

> HIV trial follow-up quashes fears of infection risk. More

And Finally... Can peanut butter help diagnose Alzheimer's disease? Report